CRISPR Therapeutics AG CRSP
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -4.69% | 56.29% | 9.61% | -250.07% | -23.85% |
| Total Depreciation and Amortization | -4.40% | -7.94% | -8.80% | 16.91% | -6.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 126.30% | -94.16% | 11.84% | 43.73% | -55.86% |
| Change in Net Operating Assets | -80.30% | 77.60% | -128.09% | 192.95% | 127.03% |
| Cash from Operations | -5.97% | 26.68% | -101.86% | -84.99% | 20.84% |
| Capital Expenditure | -459.46% | -453.85% | -144.66% | -103.54% | 66.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 88.53% | -178.48% | -1,998.52% | -64.45% | 26.17% |
| Cash from Investing | 88.19% | -179.54% | -1,979.19% | -64.85% | 26.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.50% | 267.67% | -41.84% | 589.82% | 2,978.49% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.50% | 217.98% | 5,490.37% | 589.82% | 2,978.49% |
| Foreign Exchange rate Adjustments | 122.22% | -92.50% | -178.05% | 101.15% | -136.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -206.92% | -217.51% | 214.53% | -15.88% | 135.89% |